4,390 results match your criteria implantation icd

Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers-reaching the frontiers of individual risk prediction.

Eur Heart J 2021 Jun 11. Epub 2021 Jun 11.

Heart Center, Department of Cardiology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, Netherlands.

Aims: This study aims to improve risk stratification for primary prevention implantable cardioverter defibrillator (ICD) implantation by developing a new mutation-specific prediction model for malignant ventricular arrhythmia (VA) in phospholamban (PLN) p.Arg14del mutation carriers. The proposed model is compared to an existing PLN risk model. Read More

View Article and Full-Text PDF

AnaLysIs of Both sex and device specific factoRs on outcomes in pAtients with non-ischemic cardiomyopathy (BIO-LIBRA): Design and clinical protocol.

Heart Rhythm O2 2020 Dec 10;1(5):376-384. Epub 2020 Nov 10.

Department of Cardiology, University of Washington, Seattle, Washington.

Background: Outcomes of patients with nonischemic cardiomyopathy and low ejection fraction implanted with an implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy with a defibrillator (CRT-D), especially in contemporary, real-life cohorts, are not fully understood.

Objective: We aimed to better characterize outcomes of death and ventricular tachyarrhythmias in patients with nonischemic cardiomyopathy, implanted with an ICD or CRT-D, and specifically assess differences by sex.

Methods: The AnaLysIs of Both Sex and Device Specific FactoRs on Outcomes in PAtients with Non-Ischemic Cardiomyopathy (BIO-LIBRA) study was designed to prospectively assess outcomes of device-treated ventricular tachyarrhythmias and all-cause mortality events in nonischemic cardiomyopathy patients, indicated for an ICD or CRT-D implantation for the primary prevention of sudden cardiac death (SCD), with a specific focus on sex differences. Read More

View Article and Full-Text PDF
December 2020

Electroanatomical mapping- and CT scan image integration-guided pacing lead implantation: A case series and review of the recent literature.

Heart Rhythm O2 2020 Dec 28;1(5):341-350. Epub 2020 Oct 28.

Department of Cardiology, Section for Arrhythmia, Aarhus University Hospital Skejby, Aarhus, Denmark.

Background: We present a case series and short review of electroanatomical mapping (EAM)-guided pacing lead implantation. The cases illustrate different aspects of EAM use in special circumstances and summarizes our experience with EAM-guided His lead implantation in 32 consecutive patients. Advantages and caveats encountered when using EAM in device procedures are discussed. Read More

View Article and Full-Text PDF
December 2020

Ineffective implantable cardioverter-defibrillator shocks among patients on continuous left ventricular assist device support: Clinical characteristics and management.

Heart Rhythm O2 2020 Dec 6;1(5):336-340. Epub 2020 Nov 6.

Medstar Washington Hospital Center, Washington, DC.

Background: Placement of a left ventricular assist device (LVAD) has been described to compromise implantable cardioverter-defibrillator (ICD) defibrillation threshold (DFT). Elevated DFT will have negative consequences and increases the risk of ineffective ICD shocks, morbidity, and mortality. DFT testing is not routinely performed in clinical practice, despite this fact. Read More

View Article and Full-Text PDF
December 2020

Preventive versus deferred catheter ablation of myocardial infarct-associated ventricular tachycardia: A meta-analysis.

Heart Rhythm O2 2020 Oct 14;1(4):275-282. Epub 2020 Aug 14.

Division of Cardiology, Weill Cornell Medicine - New York Presbyterian Hospital, New York, New York.

Background: The optimal timing of catheter ablation for the treatment of ventricular tachycardia (VT) in patients with ischemic cardiomyopathy remains unclear. Studies examining the impact of early preventive ablation of VT on rates of implantable cardioverter-defibrillator (ICD) therapies and mortality have been limited by small sample size.

Objectives: To conduct a meta-analysis of randomized controlled trials (RCTs) comparing initial catheter ablation and ICD implantation (preventive ablation arm) vs ICD implantation alone (deferred ablation arm) in patients with ischemic cardiomyopathy and VT. Read More

View Article and Full-Text PDF
October 2020

Implantable cardioverter-defibrillator programming after first occurrence of ventricular tachycardia in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT).

Heart Rhythm O2 2020 Jun 11;1(2):77-82. Epub 2020 May 11.

Clinical Cardiovascular Research Center, University of Rochester Medical Center, Rochester, New York.

Background: Implantable cardioverter-defibrillator (ICD) programming to novel settings can reduce the risk of inappropriate therapies.

Objective: The purpose of this study was to evaluate the impact of novel ICD programming after the first occurrence of ventricular tachycardia (VT).

Methods: In MADIT-RIT (Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy) patients who experienced a first occurrence of VT, the risk of subsequent inappropriate and appropriate ICD therapies and adverse cardiovascular events by ICD programming to Arm A (conventional: VT ≥170 bpm), Arm B (high rate: VT ≥200 bpm), or Arm C (duration delay: ≥60-second delay before therapy ≥170 bpm) was determined. Read More

View Article and Full-Text PDF

A novel screening test for inappropriate shocks due to myopotentials from the subcutaneous implantable cardioverter-defibrillator.

Heart Rhythm O2 2020 Apr 27;1(1):27-34. Epub 2020 Apr 27.

Department of Cardiology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Background: The subcutaneous implantable cardioverter-defibrillator (S-ICD) is effective in preventing sudden cardiac death. Compared with transvenous ICDs, S-ICDs have a lower rate of inappropriate shocks (IASs) for supraventricular arrhythmias, but such shocks for T-wave oversensing (TWO) and extracardiac myopotentials are more common. No screening tests to identify patients at risk for IAS due to myopotential interference (MPI) currently are available. Read More

View Article and Full-Text PDF

Prognostic value of cardiovascular magnetic resonance left ventricular volumetry and geometry in patients receiving an implantable cardioverter defibrillator.

J Cardiovasc Magn Reson 2021 Jun 10;23(1):72. Epub 2021 Jun 10.

Department of Medical Imaging, St. Michael's Hospital, Unity Health Toronto, University of Toronto, Toronto, Canada.

Background: Current indications for implantable cardioverter defibrillator (ICD) implantation for sudden cardiac death prevention rely primarily on left ventricular (LV) ejection fraction (LVEF). Currently, two different contouring methods by cardiovascular magnetic resonance (CMR) are used for LVEF calculation. We evaluated the comparative prognostic value of these two methods in the ICD population, and if measures of LV geometry added predictive value. Read More

View Article and Full-Text PDF

Non-Ischemic Sudden Cardiac Arrest: Role of 12 Lead Holter, Family Screening and Genetic Testing.

Pacing Clin Electrophysiol 2021 Jun 8. Epub 2021 Jun 8.

Division of Pacing and Electrophysiology, Rambam Health Care Campus, Haifa, Israel.

Objective: To evaluate the diagnostic and prognostic yield of a comprehensive protocol involving clinical and broad genetic testing in consecutive sudden cardiac arrest (SCA) population.

Background: Determining the pathogenesis of non-ischemic SCA is crucial for management and SCA prevention in other family members METHODS: Families with unexplained non-ischemic SCA event underwent rigorous clinical and genetic protocol after referral to our inherited arrhythmia clinic, during 2011-.2017. Read More

View Article and Full-Text PDF

How to get the optimal defibrillation lead parameters using myocardial perfusion scintigraphy in patients with coronary artery disease.

Int J Cardiovasc Imaging 2021 Jun 7. Epub 2021 Jun 7.

Department of Surgical Arrhythmology and Cardiac Pacing, Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences, Kievskaya st., 111a, Tomsk, Russian Federation, 634012.

The conventional criteria for a defibrillation lead (DL) implantation don't take into account presence of scar or deep ischemia in the myocardium. This may impair a proper functioning of the DL. We sought to optimize the DL implantation placement using rest myocardial perfusion scintigraphy (MPS), which allow detecting areas of myocardial hypoperfusion (MH). Read More

View Article and Full-Text PDF

Implantable Cardiac Defibrillator Deactivation During End-of-Life Care in the COVID-19 Pandemic.

J Am Board Fam Med 2021 May-Jun;34(3):474-476

From the Upstate Medical University, State University of New York (SEM, GLE).

People with implantable cardiac defibrillators (ICDs) who are nearing the end of life are at risk for arrhythmias, which activate the ICD and may cause unnecessary shocks and suffering. Because ICDs have enabled more patients to live longer, they often succumb to noncardiac diseases and may be cared for by primary care physicians. Despite published recommendations 10 years ago regarding the management of ICDs during the end of life, over half of patients with ICDs who are dying still have not been offered the choice of deactivation. Read More

View Article and Full-Text PDF
October 2020

Tricuspid regurgitation associated with implantable electrical device insertion: a systematic review and meta-analysis.

Pacing Clin Electrophysiol 2021 Jun 3. Epub 2021 Jun 3.

Division of Cardiac Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Background: Implantable cardioverter defibrillator (ICD) and permanent pacemaker (PPM) lead placement may worsen or result in tricuspid regurgitation (TR). While the association between lead placement and the incidence of TR has been established, current understanding of this problem remains incomplete. This systematic review and meta-analysis sought to pool the existing evidence to better understand the occurrence and severity of TR associated with cardiac implantable electrical device (CIED) insertion. Read More

View Article and Full-Text PDF

Increased long-term risk of heart failure and other adverse cardiac outcomes in dermatomyositis and polymyositis: Insights from a nationwide cohort.

J Intern Med 2021 Jun 3. Epub 2021 Jun 3.

From the, Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Background: Mounting evidence suggests that dermatomyositis/polymyositis (DM/PM) are associated with increased risk of atherosclerotic events and venous thromboembolism. However, data on the association between DM/PM and other cardiac outcomes, especially heart failure (HF), are scarce.

Objectives: To examine the long-term risk and prognosis associated with adverse cardiac outcomes in patients with DM/PM. Read More

View Article and Full-Text PDF

Impact of COVID-19 Pandemic on the Implantation of Intra-Cardiac Devices in Diabetic and Non-Diabetic Patients in the Western of Romania.

Medicina (Kaunas) 2021 May 3;57(5). Epub 2021 May 3.

Department VII, Internal Medicine II, Discipline of Cardiology, University of Medicine and Pharmacy "Victor Babes" Timisoara, E. Murgu Square, Nr. 2, 300041 Timisoara, Romania.

: COVID-19 pandemic severely impacted public health services worldwide, determining a significant decrease of elective cardiovascular (CV) procedures, especially in patients with associated chronic diseases such as diabetes mellitus (DM). : This study was first started in 2019 in the western of Romania, to analyze the differences regarding the implantations of intra-cardiac devices such as permanent pacemakers (PPM), cardiac resynchronization therapy (CRT), or implantable cardioverter-defibrillators (ICD) in 351 patients with and without DM and the situation was reanalyzed at the end of 2020. : of the first 351 patients with and without DM. Read More

View Article and Full-Text PDF

Cycle length of nonsustanied ventricular tachycardias among ICD patients: implications on subsequent appropriate therapies.

BMC Cardiovasc Disord 2021 May 31;21(1):268. Epub 2021 May 31.

Arrhythmias Unit, Cardiology Department, IBSAL-University Hospital, CIVER-CV, Universidad de Salamanca, Paseo de San Vicente, 58-182, 37007, Salamanca, Spain.

Background: ICD patients with episodes of nonsustained ventricular tachycardias (NSVT) are at risk of appropriate therapies. However, the relationship between the cycle length (CL) of such NSVTs and the subsequent incidence of appropriate interventions is unknown.

Methods: 416 ICD patients with LVEF < 45% were studied. Read More

View Article and Full-Text PDF

Changes in quality of life, depression, general anxiety, and heart-focused anxiety after defibrillator implantation.

ESC Heart Fail 2021 May 27. Epub 2021 May 27.

Department of Internal Medicine III (Cardiology, Angiology and Intensive Care), Saarland University Medical Center, Saarland University, Kirrbergerstraße 100, Homburg, Saarland, 66421, Germany.

Aims: The Anxiety-CHF (Anxiety in patients with Chronic Heart Failure) study investigated heart-focused anxiety (HFA, with the dimensions fear, attention, and avoidance of physical activity), general anxiety, depression, and quality of life (QoL) in patients with heart failure. Psychological measures were assessed before and up to 2 years after the implantation of an implantable cardioverter defibrillator (ICD) with or without cardiac resynchronization therapy defibrillator (CRT-D).

Methods And Results: One hundred thirty-two patients were enrolled in this monocentric prospective study (44/88 CRT-D/ICD, mean age 61 ± 14 years, mean left ventricular ejection fraction 31 ± 9%, and 29% women). Read More

View Article and Full-Text PDF

[The Pacemaker and Implantable Cardioverter-Defibrillator Registry of the Italian Association of Arrhythmology and Cardiac Pacing - Annual report 2019].

G Ital Cardiol (Rome) 2021 Jun;22(6):496-508

Dipartimento di Medicina Ambientale e Salute Pubblica, Università degli Studi, Padova.

Background: The pacemaker (PM) and implantable cardioverter-defibrillator (ICD) Registry of the Italian Association of Arrhythmology and Cardiac Pacing (AIAC) monitors the main epidemiological data in real-world practice. The survey for the 2019 activity collects information about demographics, clinical characteristics, main indications for PM/ICD therapy and device types from the Italian collaborating centers.

Methods: The Registry collects prospectively national PM and ICD implantation activity on the basis of European cards. Read More

View Article and Full-Text PDF

The Role of Ablation in Prevention of Recurrent Implantable Cardioverter Defibrillator Shocks in Patients With Tetralogy of Fallot.

CJC Open 2021 May 28;3(5):619-626. Epub 2021 Jan 28.

University Health Network Toronto, Peter Munk Cardiac Centre, and University of Toronto, Toronto, Ontario, Canada.

Background: Implantable cardioverter defibrillators (ICDs) are effective in preventing arrhythmic sudden cardiac death in patients with tetralogy of Fallot (TOF). Although ICD therapies for malignant ventricular arrhythmias can be life-saving, shocks could have deleterious consequences. Substrate-based ablation therapy has become the standard of care to prevent recurrent ICD shocks in patients with ischemic cardiomyopathy. Read More

View Article and Full-Text PDF

Comparative Safety of the TFN-ADVANCED Proximal Femoral Nailing System: Findings from a U.S. Health-Care Database.

J Bone Joint Surg Am 2021 May 20. Epub 2021 May 20.

Epidemiology & Real-World Data Sciences, Medical Devices, Johnson & Johnson, New Brunswick, New Jersey.

Background: Proximal femoral fractures are often treated with cephalomedullary nails. Although nail breakages following fracture repair are infrequent, a recent implant retrieval study suggested that the TFN-ADVANCED (TFNA) Proximal Femoral Nailing System (DePuy Synthes) was susceptible to post-implant breakage. It is unclear whether the risk of breakage among patients who receive the TFNA implant is higher than patients who receive other comparable cephalomedullary nails. Read More

View Article and Full-Text PDF

Antibiotic Prophylaxis and Treatment in Early Cardiac Implantable Electronic Devices Infection.

Med Arch 2021 Feb;75(1):56-60

Department of Cardiology, Queen Alia Heart Institute, Royal Medical Services, Amman, Jordan.

Background: Cardiac implantable electronic devices - PM, ICD, and CRTs- are well-proven life-sustaining and the ultimate destination for many heart conditions. Based on scientific evidence, there is a worldwide incremental increase in CIED implantations numbers.

Objective: Early infection of cardiac implantable electronic devices (CIED)- pacemaker (PM), implantable cardioverter-defibrillator (ICD), and cardiac resynchronization therapy (CRT)- is a growing health challenge. Read More

View Article and Full-Text PDF
February 2021

Cardiovascular implantable electronic devices in hemodialysis patients: an updated review.

J Cardiovasc Med (Hagerstown) 2021 May 19. Epub 2021 May 19.

Division of Nephrology, Dialysis and Renal Transplantation, ASST Grande Ospedale Metropolitano Niguarda, Milan Division of Nephrology and Dialysis, ASST Monza, Desio and San Gerardo Hospital Department of Cardiac, Thoracic, Vascular Sciences & Public Health, University of Padova, Padova Division of Cardiology, West Vicenza General Hospitals, Arzignano (Vicenza), Italy.

Cardiovascular diseases are the leading life-threatening complications in hemodialysis patients. In this scenario, both tachy-arrhythmias and brady-arrhythmias are involved with related hemodialysis and nonhemodialysis-dependent mechanisms; moreover, those arrhythmias usually occur in different time intervals before sudden cardiac death (SCD). Furthermore, current evidence shows that the presence of advanced chronic kidney disease (CKD) reduces the benefits of implantable cardioverter--defibrillators (ICDs), which increases the risk of both arrhythmic and nonarrhythmic death, especially in patients with advanced stages of heart failure. Read More

View Article and Full-Text PDF

Cardiac Resynchronization Therapy (CRT) with or without Defibrillation in Patients with Non-Ischemic Cardiomyopathy: A Systematic Review and Meta-analysis.

Circ Arrhythm Electrophysiol 2021 May 17. Epub 2021 May 17.

Heart and Vascular Institute Cleveland Clinic, Cleveland, OH.

- Cardiac resynchronization therapy (CRT) represents a major medical advance in patients with heart failure (HF) with electrical dysschrony to improve symptoms, reduce hospitalization, and increase survival both in the presence and absence of implantable-cardioverter defibrillator (ICD) therapy. However, among CRT-eligible patients with non-ischemic cardiomyopathy (NICM), the benefit of defibrillator therapy in addition to CRT remains unclear. A systematic review and meta-analysis comparing outcomes of patients with NICM and HF who underwent CRT with ICD (CRT-D) vs. Read More

View Article and Full-Text PDF

The Necessity of an ICD-Therapy in Patients with Indications for Primary Prevention of Sudden Cardiac Death. One Center Experience.

Kardiologiia 2021 May 4;61(4):24-31. Epub 2021 May 4.

Federal centers of High Medical Technologies Health Ministry Russian Federation, Kaliningrad.

Aim      Analysis of responses of cardioverter-defibrillators implanted in patients with cardiomyopathies (CMPs) of various origins and a high risk of sudden cardiac death (SCD) to assess the effectiveness of a modern strategy for primary prevention of SCD.Material and methods  In the Federal Center for High Medical Technologies in Kaliningrad from 2014 through 2018, implantable cardioverter-defibrillators (ICD) and cardiac resynchronization therapy defibrillators (CRT-D) were installed in 165 patients. Major indications for device implantation in these patients included left ventricular (LV) systolic dysfunction with ejection fraction (EF) ≤35 %; chronic heart failure (CHF) consistent with the New York Heart Association (NYHA) functional class (FC) II-III (IV for CRT-D) without previous episodes of life-threatening ventricular arrhythmias, circulatory arrest and resuscitation, which was consistent with the current international strategy for primary prevention of SCD. Read More

View Article and Full-Text PDF

Risk factors for the first and second inappropriate implantable cardioverter-defibrillator therapy.

Int J Cardiol Heart Vasc 2021 Jun 26;34:100779. Epub 2021 Apr 26.

Department of Internal Medicine, Faculty of Medicine, Kindai University, Osaka-Sayama, Japan.

Introduction: Various risk factors for the first inappropriate implantable cardioverter-defibrillator (ICD) therapy event have been reported, including a history of atrial fibrillation/atrial flutter (AF/AFL), younger age, and multiple zones. Nonetheless, which factors are concordant with real-world data has not been clarified, and risk factors for the second inappropriate ICD therapy event have not been well examined. This study aimed to clarify the risk factors for the first and second inappropriate ICD therapy events. Read More

View Article and Full-Text PDF

Effective treatment of electrical storm by a wearable cardioverter defibrillator in a patient with severely impaired left ventricular function after myocardial infarction: a case report.

J Med Case Rep 2021 May 17;15(1):243. Epub 2021 May 17.

Department of Cardiology, Brandenburg Medical School Theodor Fontane, Brandenburg an der Havel, Germany.

Background: The implantation of cardioverter defibrillators (ICDs) is an established therapy in the prevention of sudden cardiac death in patients with systolic dysfunction after myocardial infarction. To avoid immediate implantation of an ICD, wearable cardioverter defibrillator vests (WCD) can be used to protect patients against malignant rhythm disorders, while at the same time drug-based heart failure therapy has to be initiated. This drug therapy can improve left ventricular ejection fraction and primary prophylactic cardioverter defibrillator implantation may not be necessary. Read More

View Article and Full-Text PDF

Long-term evaluation of sensing variability of a floating atrial dipole in a single‑lead defibrillator: The mechanistic basis of long-term stability of amplified atrial electrogram.

Int J Cardiol 2021 May 13. Epub 2021 May 13.

Division of Cardiology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address:

Background: A single‑lead implantable cardioverter-defibrillator (ICD) with a floating atrial dipole has been developed to enhance the diagnostic capability of atrial arrhythmias and to facilitate adjudication of arrhythmic events without the additional effort required for atrial lead insertion. However, there have been concerns about the long-term reliability of atrial sensing.

Methods: We enrolled patients with the single-chamber ICD with atrial-sensing electrodes from 4 tertiary university hospitals in Korea. Read More

View Article and Full-Text PDF

Prognosis of the non-ST elevation myocardial infarction complicated with early ventricular fibrillation at higher age.

Geroscience 2021 May 14. Epub 2021 May 14.

Heart and Vascular Center, Semmelweis University, Városmajor u. 68, Budapest, 1122, Hungary.

Early ventricular fibrillation (EVF) predicts mortality in ST-segment elevation myocardial infarction (STEMI) patients. Data are lacking about prognosis and management of non-ST-segment elevation myocardial infarction (NSTEMI) EMI with EVF, especially at higher age. In the daily clinical practice, there is no clear prognosis of patients surviving EVF. Read More

View Article and Full-Text PDF

Long-term survival after Carpentier-Edwards Perimount aortic valve replacement in Western Denmark: a multi-centre observational study.

J Cardiothorac Surg 2021 May 14;16(1):130. Epub 2021 May 14.

Department of Cardiac, Thoracic and Vascular Surgery, Odense University Hospital, J. B. Winsløws Vej 4, 5000, Odense C, Denmark.

Background: This study describes the long-term survival, risk of reoperation and clinical outcomes of patients undergoing solitary surgical aortic valve replacement (SAVR) with a Carpentier-Edwards Perimount (CE-P) bioprosthetic in Western Denmark. The renewed interest in SAVR is based on the questioning regarding the long-term survival since new aortic replacement technique such as transcatheter aortic-valve replacement (TAVR) probably have shorter durability, why assessment of long-term survival could be a key issue for patients.

Methods: From November 1999 to November 2013 a cohort of a total of 1604 patients with a median age of 73 years (IQR: 69-78) undergoing solitary SAVR with CE-P in Western Denmark was obtained November 2018 from the Western Danish Heart Registry (WDHR). Read More

View Article and Full-Text PDF

The use of laser lead extraction sheath in the presence of supra-cardiac occlusion of the central veins for cardiac implantable electronic device lead upgrade or revision.

PLoS One 2021 14;16(5):e0251829. Epub 2021 May 14.

Department of Cardiac Surgery, Heidelberg University Hospital, Heidelberg, Baden-Würrtemberg, Germany.

Background: The implantation of cardiac implantable electronic devices (CIED) has increased in the last decades with improvement in the quality of life of patients with cardiac rhythm disorders. The presence of bilateral subclavian, innominate or superior vena cava obstruction is a major limitation to device revision and/or upgrade.

Methods And Material: This is retrospective study of patients who underwent laser-assisted lead extraction (LLE) (GlideLight laser sheath, Spectranetics Corporation, Colorado Springs, USA) with lead revision or upgrade using the laser sheath as a guide rail. Read More

View Article and Full-Text PDF

[The wearable cardioverter defibrillator as diagnostic tool : Case report from remote monitoring daily practice].

Herzschrittmacherther Elektrophysiol 2021 Jun 12;32(2):264-268. Epub 2021 May 12.

Katholisches Klinikum Lünen / Werne St.-Marien-Hospital Lünen, Medizinische Klinik 1, Lünen, Deutschland.

Telemedical care can point out new applications of already established therapeutics such as a wearable cardioverter-defibrillator (WCD) and improve the quality of care for chronically ill patients with heart failure through improved management of data derived from this device. The current case report describes the clinical course of a 71-year-old man, who was treated with a WCD in accordance with the current guidelines until a final decision was made about ICD implantation, after acute cardiac decompensation and lately diagnosed severe decrease of left ventricular function in the context of ischaemic cardiomyopathy. The data collected by the WCD were evaluated in a structured way via a telemedicine centre (TMC) and recurrence of the previously known paroxysmal atrial fibrillation (AF) was discovered. Read More

View Article and Full-Text PDF